Evidence map›Paper›PMID 32463824›Full record

Trial reportPloS one2020

Characterization of occult hepatitis B in high-risk populations in Kenya.

Kiptoon Beatrice Jepkemei, Missiani Ochwoto, Ken Swidinsky, Jacqueline Day, Henok Gebrebrhan, Lyle R McKinnon, Anton Andonov, Julius Oyugi, Joshua Kimani, George Gachara and 2 more

Open access · goldAbstract readClinical TrialMulticenter Study
In one paragraph

Trial report in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Control of occult hepatitis B virus infection.Advances in laboratory medicine · 2022
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Kiptoon Beatrice JepkemeiNational Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.ORCID 0000-0001-9487-817X
Missiani OchwotoKenya Medical Research Institute, Nairobi, Kenya.
Ken SwidinskyNational Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.
Jacqueline DayNational Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.
Henok GebrebrhanDepartment of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Manitoba, Canada.
Lyle R McKinnonDepartment of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Manitoba, Canada.
Anton AndonovNational Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.
Julius OyugiDepartment of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Manitoba, Canada.
Joshua KimaniDepartment of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Manitoba, Canada.
George GacharaDepartment of Medical Laboratory Sciences, Kenyatta University, Nairobi, Kenya.ORCID 0000-0001-5428-9565
Elijah Maritim SongokKenya Medical Research Institute, Nairobi, Kenya.
Carla OsiowyNational Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.ORCID 0000-0002-5429-7220
Public Health Agency of Canada · CAUniversity of Nairobi · KEKenya Medical Research Institute · KEKenyatta University · KEUniversity of Manitoba · CA

Funding

CIHR
6 · The paper itself

Abstract

Occult hepatitis B infection (OBI) is defined as the presence of hepatitis B virus (HBV) DNA in the liver or serum in the absence of detectable HBV surface antigen (HBsAg). OBI poses a risk for the development of cirrhosis and hepatocellular carcinoma. The prevalence of OBI in Kenya is unknown, thus a study was undertaken to determine the prevalence and molecular characterization of OBI in Kenyan populations at high risk of HBV infection. Sera from two Nairobi cohorts, 99 male sex workers, primarily having sex with men (MSM-SW), and 13 non-MSM men having HIV-positive partners, as well as 65 HBsAg-negative patients presenting with jaundice at Kenyan medical facilities, were tested for HBV serological markers, including HBV DNA by real-time PCR. Positive DNA samples were sequenced and MSM-SW patients were further tested for hepatitis C virus (HCV) infection. Of the 166 HBsAg-negative samples tested, 31 (18.7%; 95% confidence interval [CI] 13.5-25.3) were HBV DNA positive (i.e., occult), the majority (20/31; 64.5%) of which were HBV core protein antibody positive. HCV infection was not observed in the MSM-SW participants, although the prevalence of HBsAg positivity was 10.1% (10/99; 95% CI 5.6-17.6). HBV genotype A was predominant among study cases, including both HBsAg-positive and OBI participants, although the data suggests a non-African network transmission source among MSM-SW. The high prevalence of HBV infection among MSM-SW in Kenya suggests that screening programmes be instituted among high-risk cohorts to facilitate preventative measures, such as vaccination, and establish entry to treatment and linkage to care.

Indexed as

Hepatitis BHepatitis B virusHomosexuality, MaleSex WorkersCarcinoma, HepatocellularFemaleHepacivirusHepatitis B AntibodiesHepatitis B Surface AntigensHepatitis CHumansKenyaLiver NeoplasmsMalePrevalenceHepatitis B AntibodiesHepatitis B Surface Antigens

Identifiers

PMID32463824
PMCPMC7255601
OpenAlexW3032311445

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.